Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody
Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody Summary
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of ErbB2/Her2 in MCF-7 human cell line by Flow Cytometry. MCF-7 human cell line was stained with Human Anti-Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Monoclonal Antibody (Catalog # MAB9589, filled histogram) or Human IgG Control Antibody (1-001-A, open histogram) followed by APC-conjugated Anti-Human IgG Secondary Antibody (Catalog # F0135). View our protocol for Staining Membrane-associated Proteins.
Detection of ErbB2/Her2 in MDA-MB-453 human cell line by Flow Cytometry. MDA-MB-453 human cell line was stained with Human Anti-Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Monoclonal Antibody (Catalog # MAB9589, filled histogram) or Human IgG Control Antibody (1-001-A, open histogram) followed by APC-conjugated Anti-Human IgG Secondary Antibody (Catalog # F0135). View our protocol for Staining Membrane-associated Proteins.
Inhibition of Cell Proliferation by ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody. Human Anti-Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Monoclonal Antibody (Catalog # MAB9589) inhibits proliferation in the SK-BR-3 human breast cancer cell line as measured by Resazurin (Catalog # AR002). The ED50 for this effect is typically 15-75 ng/mL.
NKs cells are potent killers in ADCC assays with SKOV-3 or Raji cells (A, B) ADCC assays with SKOV-3 and Raji targets. NK cells were cultured as described in the adjacent figure for 13 days. Prior to setting up the ADCC assay, CD56+CD16+ levels were ascertained to be >30% on NKs using Human Fc gamma RIII (CD16) PerCP-conjugated Antibody (FAB2546C); in our hands, this is the minimum level required for killing via ADCC. Target cells were labeled with Mito Mark Green (SKOV-3 or Raji), and Effectors/NKs were labeled with Janelia Fluor 646 as described (Figure 1). (A) SKOV-3 cells were preincubated with 5 ug/mL Anti-Her2/Trastuzumab (Catalog # MAB9589); (B) Raji cells were preincubated with 10 ug/mL Anti-CD20/Rituximab (MAB9630), both for 30 minutes at room temperature prior to setting up the ADCC assay with the NKs. 0.5:1 E:T ratios were used for the SKOV-3/Trastuzumab model, and NKs and SKOV-3 cells were co-incubated for 2 hours at 37°C. 2:1 E:T ratios were used for the Raji/Rituximab model, and NKs and Raji cells were co-incubated for 2.5 hours at 37°C. In both models, the cells were harvested, stained with antibodies for Human CD3 Alexa Fluor 405 and Human CD56 Alexa Fluor 700, and analyzed by flow cytometry. Importantly, non-NKs (JF 646-CD56- cells) are shown in the Mito Mark dye graphs that depict killing. These results are representative of 3+ experiments.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Trastuzumab is a biosimilar directed against the extracellular domain of Her2 (ErbB2). This product constitutes the immunogen used for the anti-Idiotype catalog numbers MAB9547 and MAB95471. The biotinylated antibody (catalog number FAB9589B) can be used in flow cytometry or various assay formats to measure Her2 expression and can be detected by conjugated streptavidin.
Citations for Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
NL-201 upregulates MHC-I expression and intratumoral TCR diversity, and demonstrates robust antitumor activity as monotherapy and in combination with PD-1 blockade
Authors: Mortales, C;Dutzar, B;Chen, J;Chen, A;Huard, J;Walkey, C;Swanson, R;
Cancer immunology research
Sample Types: Whole Cells
Applications: Flow Cytometry
Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota
Authors: T Vogl, S Klompus, S Leviatan, IN Kalka, A Weinberger, C Wijmenga, J Fu, A Zhernakova, RK Weersma, E Segal
Nature Medicine, 2021-07-19;0(0):.
Species: Staphylococcus, Streptococcus
Applications: Neutralization Control
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells
Authors: Y Chen, R Wang, S Huang, ES Henson, J Bi, SB Gibson
Sample Types: Cell Lysates
Applications: Immunoprecipitation, Western Blot
What is a Biosimilar antibody?
A Biosimilar antibody is a non-therpeutic, recombinantly-expressed antibody which has the same sequence as the corresponding therapeutic antibody. It is for research use only. The nomenclature of the Biosimilar antibody includes the name of the therapeutic antibody. For example, Catalog # MAB9577 is called Human EGFR (Research Grade CetuxiMab Biosimilar) antibody.
Does this Biosimilar antibody have the same sequence as its corresponding therapeutic antibody?
This Biosimilar antibody has the same variable region sequence as the therapeutic antibody, but the constant region is not the same. It contains a proprietary human IgG constant region.
Is an isotype control available for human IgG Biosimilar Antibodies?
Unfortunately, we do not offer isotype controls for Biosimilar antibodies at this time. We do have a polyclonal Normal Human IgG Control, Catalog # 1-001-A.
Reviews for Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody
Average Rating: 3.5 (Based on 2 Reviews)
Have you used Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image